RecruitingPhase 4NCT07142343
A Study to Test the Safety of Pozelimab in Pediatric Participants 1 to 5 Years of Age With a Rare Disease Called CHAPLE (Complement Hyperactivation, Angiopathic Thrombosis, Protein-losing Enteropathy) Disease
Studying Complement hyperactivation-angiopathic thrombosis-protein-losing enteropathy syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Regeneron Pharmaceuticals
- Principal Investigator
- Clinical Trial ManagementRegeneron Pharmaceuticals
- Intervention
- Pozelimab(drug)
- Enrollment
- 5 enrolled
- Eligibility
- 1-5 years · All sexes
- Timeline
- 2026 – 2030
Study locations (1)
- Marmara University Hospital, Istanbul, Turkey (Türkiye)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07142343 on ClinicalTrials.gov